IFF · Q1 2026 Earnings

Cautious

International Flavors & Fragrances

Reported May 5, 2026

30-second summary

Q1 EBITDA of $568M came in well above the ~$505M PY base management had framed as "modest growth," driving FY26 reaffirmation across every metric — but the reaffirmation is now openly engineered: management explicitly said the year's shape has changed, with Q1 strength offset by a Q2 where absolute EBITDA dollars will fall below $568M on Middle East fine-fragrance softness, fine-fragrance volume disruption, and inflation hitting before pricing actions fully land. The Food Ingredients sale narrative continued to fade — no new process detail — and H&B CN growth at +5% in Q1 came in below the Q4 trajectory readers had flagged, partially validating the "single-quarter print" concern flagged last brief.

Headline numbers

EPS

Q1 FY2026

$1.25

Revenue

Q1 FY2026

$2.74B

-4.0% YoY

Gross margin

Q1 FY2026

37.1%

Free cash flow

Q1 FY2026

$0.09B

Operating margin

Q1 FY2026

10.0%

Key financials

Q1 FY2026

Metric	Q1 FY2026	YoY	Q4 FY2025	QoQ
Revenue	$2.74B	-4.0%	$2.59B	+5.9%
EPS	$1.25	—	$0.80	+56.2%
Gross margin	37.1%	—	34.4%	+270bps
Operating margin	10.0%	—	3.7%	+626bps
Free cash flow	$0.09B	—	—	—

Guidance

Full-year FY2026 guidance fully reaffirmed across revenue, EBITDA, and growth metrics; Q1 EBITDA beat expectations, but Q2 signaled to be materially weaker with absolute EBITDA dollars expected below Q1's $568M due to volume pressure, input cost headwinds, and fine fragrance softness.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

Metric	Period	Prior guide	Actual	Δ	Result
Adjusted Operating EBITDA	Q1 FY2026	Modest growth versus like-for-like Q1 2025 base of approximately $505 million	$568 million	+$63 million above guide (12.5% above base)	Beat

New guidance

Metric	Period	Guide	YoY
Adjusted Operating EBITDA	Q2 FY2026	Expected to be lower than $568 million reported in Q1 2026	—

Changes to prior guidance

Metric	Period	Prior guide	New guide	Δ	Result
CapEx as % of Sales	FY2026	Around 6%	Withdrawn — no replacement	—	Withdrawn

Reaffirmed unchanged this quarter: Adjusted Operating EBITDA ($2.05 billion to $2.15 billion), Sales (Revenue) ($10.5 billion to $10.8 billion), Comparable Currency Neutral Sales Growth (1% to 4%), Comparable Currency Neutral Adjusted Operating EBITDA Growth (3% to 8%), Foreign Exchange Impact on Sales (Approximately 1% positive impact on sales growth), Foreign Exchange Impact on Adjusted Operating EBITDA Growth (No impact on adjusted operating EBITDA growth), Divestitures Impact (Approximately 5% adverse impact on both sales and adjusted operating EBITDA growth)

Segment KPIs

Q1 FY2026

Segment	Q1 FY2026	YoY
Taste	$0.656B	+2.0%
Health & Biosciences	$0.595B	+5.0%
Scent	$0.651B	+1.0%
Food Ingredients	$0.839B	+3.0%
Taste Segment EBITDA Margin	23.3%	—
Health & Biosciences EBITDA Margin	25.7%	—
Scent Segment EBITDA Margin	22.7%	—
Food Ingredients EBITDA Margin	13.6%	—

Other KPIs

Q1 FY2026

Segment	Q1 FY2026
Adjusted Operating EBITDA Margin	20.7%
Free Cash Flow	$92 million
Net Debt to Credit Adjusted EBITDA	2.5x
Currency Neutral Sales Growth (Comparable)	3%

Management tone

Q2 FY25 innovation-deferred-to-2026/27 → Q3 FY25 execution-only with Q4 flagged as a challenge → Q4 FY25 portfolio optimization replacing growth ambition → Q1 FY26 reaffirmation engineered by Q1 beat with explicit Q2 weakness.

The full-year reaffirmation is now openly framed as risk mitigation rather than organic confidence. Three quarters ago management was reaffirming on the strength of an innovation pipeline; this quarter the framing is mechanical: "de-risks the balance of the year and gives us the confidence to reaffirm our full year 2026 financial guidance ranges despite this uncertain environment." The Q1 outperformance is the cushion, not the trajectory. That is a meaningful shift from the multi-quarter pattern of reaffirming-while-walking-to-the-low-end — this quarter management is reaffirming-while-walking-down-the-interim-path.

Q2 has been pre-cut in absolute dollar terms — the first time in the prior-brief sequence management has guided forward EBITDA dollars lower sequentially. The anchor: "we expect absolute EBITDA dollars in the second quarter to be lower than the $568 million reported in the first quarter, potentially driven by lower volume, unfavorable price-to-input costs, and weaker mix." In Q3 FY25 management flagged Q4 "as a challenge"; in Q4 FY25 management qualitatively framed Q1 as "modest growth." This quarter the language hardens into an absolute dollar step-down — a different register, and the most concrete sequential-decline signal in five quarters.

Middle East has been promoted from "general macro uncertainty" to a quantified, segment-specific profitability headwind. A quarter ago there was no Middle East line item; this quarter management identified it as "our most significant exposure...within our scent business and our fine fragrance business in particular," with both demand softness and supply-chain disruption flagged. This is a new, concrete risk factor that did not exist in the Q4 FY25 narrative, and it is the proximate cause of the Q2 EBITDA step-down.

Pricing has shifted from "assumption" to "phased implementation with a timing mismatch." Q4 FY25 management talked about pricing as "slightly down" in fragrance and food ingredients within a volume-driven growth thesis. This quarter management acknowledged the asymmetry: "costs will begin to increase and our pricing actions are not fully implemented...we expect these inflationary trends to adversely impact profitability in the second quarter of 2026...inflationary pressure expected to gradually ease through the back half of the year as pricing actions take full effect." The implication is that H1 margins compress before H2 margins recover — and the FY range holds only if both legs of that trade land.

Recurring themes management leaned on this quarter:

Portfolio simplification and focus enabling execution confidenceMiddle East conflict creating temporary supply chain and demand disruptionPricing lag creating Q2 profitability pressure before relief in H2Volume growth across all segments driving margin expansionWorking capital discipline and cash flow accelerationInnovation and commercial pipeline advancement supporting full-year reaffirmation

Risks management surfaced:

Ongoing Middle East conflict creating logistics and supply chain disruptionInflationary pressures building through 2026, particularly energy and logistics costsFine fragrance volume softness in Middle East expected in Q2Unfavorable price-to-info cost mix in commodity fragrance ingredientsUncertainty in macroeconomic environment globally

Q&A highlights

Gansham Punjabi · Baird

What drove the strong ad performance and upside in Q1? Did the company benefit from out-of-pattern ordering or customer pre-buying?

Strong performance driven by volume-led growth across all segments and continued solid productivity. Management confirmed no indication of significant pre-buy activity.

Volume-led growth across all segmentsContinued solid productivityNo significant pre-buy detected

Nicola Tang · BNP Paribas

What assumptions on pricing and input inflation are baked into the top line outlook? What is the magnitude and expected offset rate?

Brent crude significantly up versus 2025 average, driving double-digit increases in energy and logistics. Raw material inflation expected later in year. Management implementing pricing surcharges and expects full offset within 12-18 months per historical patterns. Inventory provides near-term protection on raw materials.

Double-digit energy and logistics cost increases already materializingPricing surcharges underway, building throughout quarterExpect 12-18 month offset period for inflation historicallyInventory provides near-term raw material cost protection

Kristen Owen · Oppenheimer

Given strong Q1 results, what scenarios and conditions are needed to achieve high-end versus low-end of full-year guidance?

High-end achievement requires end-market demand improvement; low-end driven by continued weak consumer demand. EBITDA range driven by inflation offset through pricing (3-8% range reflects pricing variability). Strong innovation and commercial pipeline supports confidence despite inflationary headwinds.

No fundamental change in weak consumer demand assumed in base caseEnd market demand improvement needed for high-end guidance3-8% EBITDA range driven by pricing offset capabilityStrong innovation and commercial pipeline provides confidence

Michael Sison · Wells Fargo

At what point does inflation flowing through pricing start to impact consumer demand and demand destruction?

Management expects solid demand to continue. Fine fragrance expected to show solid but below double-digit growth; temporary Middle East slowdown noted. Consumer fragrance pipeline strong with good innovation interest. Commodity ingredients business challenged but represents only portion of fragrance sales.

Fine fragrance: continued solid growth but below prior double-digit ratesFine fragrance: temporary slowdown in important Middle East marketConsumer fragrance: strong pipeline with good innovation interestCommodity ingredients: approximately half of fragrance ingredient sales

Lawrence Alexander · Jefferies

Update on strategic goal to recoup segment share positions with flat to higher gross margins. Timeline and potential three-to-five year impact?

Good progress across portfolio. Health and biosciences: strong enzyme progress, grain processing improving. Health area undergoing turnaround with strong leadership and commercial/innovation pipelines, expected to inflect in H2 2026 and accelerate into 2027. Scent: strong fine fragrance position, commodity ingredients being de-emphasized. Food ingredients: EBITDA margins improved from 9% (2023) to 13% (2025) to expected 14%+ (2026). TAFE delivering strong quarters ahead of market.

Health area: turnaround expected H2 2026 with acceleration into 2027Food ingredients EBITDA margins: 9% (2023) → 12% (2024) → 13% (2025) → 14%+ expected (2026)Scent commodity ingredients: being de-emphasized, should improve by 2027Grain processing: opportunity for further improvement

Answers to last quarter's watch list

Whether FY26 comparable CN EBITDA growth of 3–8% holds through Q1 reporting — Q1 EBITDA of $568M beat the ~$505M PY base by ~12.5%, well clear of the low-single-digit "modest growth" framing. The FY range held without a low-end walk — the first time management has not pre-tilted the FY to the low end.

Resolved positively

Food Ingredients sale — does a defined process emerge by mid-2026 — No new disclosure on a defined process, no timeline, no value framework. The Q4 "no pressure to sell" framing was not contradicted. The "absolute clarity in 2026" commitment from Q2 FY25 has now slipped through three quarters.

Resolved negatively

FY26 FCF tracking against an unstated target — Q1 FCF of $92M was disclosed, with management citing working capital discipline and cash flow acceleration as a theme. No dollar target reintroduced; management explicitly said it will refrain from a specific FY target until there is clarity on Food Ingredients, but expects FY26 FCF to be better than FY25.

Continue monitoring

Pricing trajectory in fragrance ingredients and food ingredients — Management explicitly flagged "unfavorable price-to-input costs" as a Q2 driver, with surcharges being layered in and a 12–18 month historical offset window. The Q4 "slightly down" pricing assumption is now being actively reversed via surcharges, but the offset lag means H1 margins compress before H2 recovers.

Resolved negatively

H&B sustaining the Q4 trajectory — Q1 H&B grew +5% CN / +10% reported. Margin at 25.7% held within the band. Management framed H&B as inflecting in H2 2026 with acceleration into 2027; the underlying trend is still positive but the prior-quarter comparison should be put on a CN-to-CN basis to be meaningful.

Continue monitoring

Net leverage direction — 2.5x at Q1, described by management as "slightly below last quarter." Sub-3.0x comfort zone maintained despite the lower-FCF dynamics flagged for FY26.

Resolved positively

What to watch into next quarter

Q2 FY26 absolute EBITDA vs. the $568M Q1 print — management has explicitly guided below $568M; watch the magnitude. A drop of >$30M (more than ~5%) would suggest the FY range is at risk even with Q1's cushion. A drop within $10–15M would validate the "engineered shape" narrative without breaking the range.

Middle East fine fragrance — duration of the disruption — management framed it as "temporary." Q3 reporting will reveal whether this was a one-quarter issue or a sustained drag. Watch Scent segment growth specifically; a Q3 Scent CN print below +1% would suggest the Middle East impact is structural rather than transient.

Pricing surcharge realization in H2 — management's FY range hinges on inflation easing and pricing actions taking effect by H2. Watch H2 EBITDA margin sequencing: Q3 needs to show recovery above Q2 for the offset thesis to remain credible, and Q4 needs to demonstrate the full pricing benefit.

Food Ingredients sale process — third consecutive quarter without a defined process, though management indicated an update by the Q2 earnings call. Watch whether that update materializes; further silence increasingly suggests the optionality posture is permanent and the binary catalyst flagged through 2025 is off the table.

H&B trajectory on a consistent basis — management framed H&B as inflecting in H2 2026 with acceleration into 2027. Watch Q2 H&B CN growth vs. Q1's +5% CN; a step-up would confirm the inflection thesis, deceleration would suggest the Q4 reported print was an outlier.

FY26 FCF run-rate — Q1 FCF of $92M is encouraging. Management has declined to reinstate a specific target until Food Ingredients clarity emerges, but committed to year-over-year improvement vs. FY25. Watch H1 cumulative FCF as the next read on whether management reintroduces an explicit number.

Sources

IFF Q1 FY2026 Press Release — https://www.sec.gov/Archives/edgar/data/51253/000005125326000015/q12026991pressreleaseofiff.htm
IFF Q1 FY2026 Earnings Conference Call Transcript — May 6, 2026

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.